Glycosmedia Weekly Diabetes News - 11/13/2020

National Diabetes Audit Non-Diabetic Hyperglycaemia, 2018- 2019, Diabetes Prevention Programme

The NHS Diabetes Prevention Programme (NHS DPP) is a joint commitment from NHS England, Public Health England and Diabetes UK to deliver, at scale, evidence based behavioural interventions that can prevent or delay the onset of Type 2 diabetes in adults who have been identified as having non-diabetic hyperglycaemia (NHS Digital)

National Diabetes Audit – Care Processes and Treatment Targets, 1st Quarter ,January to June 2020

This is the quarterly release of data from the National Diabetes Audit (NDA). It is the mid-year data release for the first extraction of NDA 2020-21 data. It shows progress to date covering the period 1 January to 30 June 2020 (NHS Digital)

Lifestyle Intervention With or Without Lay Volunteers to Prevent Type 2 Diabetes in People With Impaired Fasting Glucose and/or Nondiabetic Hyperglycemia

The Norfolk Diabetes Prevention lifestyle intervention reduced the risk of type 2 diabetes in current high-risk glycemic categories. Enhancing the intervention with DPM did not further reduce diabetes risk. These translatable results are relevant for current diabetes prevention efforts (JAMA)

Visit‐to‐visit variability of clinical risk markers in relation to long‐term complications in type 1 diabetes

In type 1 diabetes, higher variability of basic clinical risk markers adds important risk stratification information for the development of micro‐ and macrovascular complications (Diabetic Medicine)

Association of Serum 25-Hydroxyvitamin D Concentrations With All-Cause and Cause-Specific Mortality Among Individuals With Diabetes

Higher serum 25(OH)D levels were significantly associated with lower all-cause and CVD mortality. These findings suggest that maintaining adequate vitamin D status may lower mortality risk in individuals with diabetes (Diabetes Care)

Risk of cardiac autonomic neuropathy in latent autoimmune diabetes in adults is similar to type 1 diabetes and lower compared to type 2 diabetes: a cross sectional study

This is the first study offering a comparative evaluation of cardiac autonomic neuropathy among LADA, type 1 and type 2 diabetes, showing a lower risk of cardiac autonomic neuropathy in LADA compared to type 2 diabetes and similar compared to type 1 diabetes. This disparity was not due to differences in age, metabolic control or cardiovascular risk factors (Diabetic Medicine)

Durability of glycaemic control in type 2 diabetes: A systematic review and meta‐analysis for its association with body weight changes

Modest weight loss with a goal of 2‐3% of body weight should be recommended to improve therapeutic durability and prevent beta‐cell deterioration (Diabetes, Obesity and Metabolism)

Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study

In patients with T2DM, SGLT2i as first-line treatment may be associated with decreased events of heart failure hospitalization, acute coronary syndrome, and all-cause mortality, compared with metformin as first-line treatment. However, there may be an increased events of ischemic stroke using SGLT2i compared to metformin (Cardiovascular Diabetology)

Integrated personalized diabetes management goes Europe: A multi-disciplinary approach to innovating type 2 diabetes care in Europe

Building on an iterative six-step disease management process that leverages feedback loops and utilizes commodity digital tools, the PDM-ProValue study program demonstrated that integrated personalized diabetes management, or iPDM, can improve the standard of care for persons living with diabetes in a sustainable way (Primary Care Diabetes)